Champions Oncology Q1 Revenue Rises 8.8% on Research Services Strength
CSBR is trading near its 52-week low of $4.83 (5.5% above the low).
Summary
Champions Oncology reported fiscal Q1 revenue of $15.23 million, up 8.8% year-over-year, driven by improved study execution and conversion in its core research services business. Oncology services margin expanded to 51% from 43% a year ago, helped by higher revenue and lower third-party radiolabeling costs. Adjusted EPS came in at $0.05. The company did not provide specific guidance for the current quarter or full year. This follows a fiscal 2026 that saw record revenue of $59.4 million but a net loss of $1.2 million and negative operating cash flow, leaving only $4.9 million in cash. The margin improvement and revenue growth are positive signals, but the lack of guidance and tight cash position remain key considerations.
At the time of this announcement, CSBR was trading at $5.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.9M. The 52-week trading range was $4.83 to $8.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.